FAQ Library

FAQ Library published on September 27, 2016
Join Dr. Orlowski as he discusses how to select between carfilzomib and ixazomib as a proteosome inhibitor, especially in the relapsed or refractory setting.
FAQ Library published on September 14, 2016
Join Dr. Richter as he explains the clinical significance of minimal residual disease (MRD) testing in multiple myeloma.
FAQ Library published on September 8, 2016
Join Dr. Orlowski as he explains how he decides between using a doublet or a triplet salvage regimen for his multiple myeloma patients.
FAQ Library published on August 18, 2016
Join Dr. Lonial as he explains how the new International Myeloma Working Group definition of active multiple myeloma will affect clinical practice.
FAQ Library published on August 11, 2016
Join Dr. Landgren as he explains how immunotherapeutic agents and monoclonal antibodies fit into the real-world treatment of patients with multiple myeloma.
FAQ Library published on August 3, 2016
Join Dr. Giralt as he explains the new recommended baseline workup tests for multiple myeloma.
FAQ Library published on July 18, 2016
Dr. Lonial discusses how to determine which patients will benefit the most from treatment with daratumumab and elotuzumab.
FAQ Library published on July 14, 2016
Join Dr. Landgren as he discusses the progression from two- to three-drug regimens, the major clinical benefits of both, and the future direction of combination therapy.
FAQ Library published on July 6, 2016
Dr. Sagar Lonial discusses the need for SPEP, UPEP, and immunofixation testing in newly diagnosed multiple myeloma patients, in patients undergoing therapy, or in relapsed and refractory patients.
FAQ Library published on June 15, 2016
In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses whether BD or KD should be considered a standard of care in relapsed/refractory multiple myeloma.
Page 3 of 12
Results 21 - 30 of 118